Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

NCT02391727 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Colon Cancer, Breast Cancer, Cancer of the Head and Neck

Interventions

BIOLOGICAL: SYN004

Sponsor

Synermore Biologics Co., Ltd.